Beyond Project Status: System Shift as a Structural Diagnostic Framework for Predicting Delay, Stagnation, and Adaptive Progression in Pharmaceutical Development Portfolios

Abstract

Project stagnation in pharmaceutical development portfolios is often recorded administratively but insufficiently diagnosed structurally. This study introduces and empirically examines System Shift as a structural diagnostic framework for reading delay, stagnation, adaptive progression, and success in pharmaceutical development portfolios. The framework operationalizes seven dimensions: System Condition, Domain Lock, Actor Complexity, Chokepoint Severity, Position Quality, Strategy Quality, and Feedback Maturity. The empirical setting is an exploratory, coded dataset of 41 project-level cases drawn from a broader portfolio of 112 pharmaceutical development projects. Results provide strong exploratory support for the framework. Chokepoint Severity showed a very strong association with Delay_Months (r = 0.9318; R² = 0.8682; slope = 1.8202), while Feedback Maturity and Strategy Quality positively predicted Success and Progression. The composite System_Shift_Risk_Score outperformed a status-only model in predicting Delay, Success, and Progression. Four visual analyses further strengthen the evidence: a correlation heatmap reveals a clear pressure-versus-adaptation architecture; a regression plot shows the functional relationship between chokepoints and delay; a feature-importance chart shows the comparative predictive salience of risk and feedback variables; and a cluster plot distinguishes low-risk adaptive, high-chokepoint stagnant, and transitional cases. The paper argues that System Shift offers an empirically promising diagnostic pathway for portfolio governance in complex pharmaceutical development systems. Because the sample is small, single-site, and first-pass coded, the study is best interpreted as exploratory empirical validation rather than final generalizable proof.